Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.40
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.30 (8.571%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.40
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Jan 2015 15:58

RNS Number : 6667D
Allergy Therapeutics PLC
30 January 2015
 



For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Allergy Therapeutics PLC

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation: iii

SOUTHERN FOX INVESTMENTS LTD.

4. Full name of shareholder(s)

(if different from 3.): iv

CHASE NOMINEES LTD -CMBLJPPB

5. Date of the transaction and date on which the threshold is crossed or reached: v

23rd January, 2015

6. Date on which issuer notified:

30th January, 2015

7. Threshold(s) that is/are crossed or

reached: vi, vii

Over 27.21%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ord GBP 0.01

 

GB00B02LCQ05

108,512,784

108,512,784

111,589,283

111,589,283

 

27.21%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/ConversionPeriod xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exerciseprice

Expirationdate xvii

Exercise/Conversionperiod xviii

Number of votingrights instrumentrefers to

% of voting rights xix, xx

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 111,589,283

 27.21%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 SOUTHERN FOX INVESTMENTS LTD

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

14. Contact name:

 George O' Carroll

15. Contact telephone number:

 +353-61-472019

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLURVVRVBAAOAR
Date   Source Headline
21st Jun 20239:38 amRNSForm 8.5 (EPT/RI)
20th Jun 202312:49 pmRNSForm 8.5 - Allergy Therapeutics plc
20th Jun 20239:57 amBUSForm 8.3 - The Allergy Therapeutics Plc
20th Jun 20239:05 amRNSForm 8.5 (EPT/RI)
19th Jun 20237:30 amRNSRestoration - Allergy Therapeutics PLC
19th Jun 20237:01 amRNSInterim Results and Lifting Suspension in Trading
19th Jun 20237:00 amRNSPublication of Annual Report and Accounts 2022
9th Jun 20237:00 amRNSAllergy Therapeutics shares key findings at EAACI
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
27th Apr 20232:15 pmRNSResult of General Meeting
24th Apr 20237:00 amRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc
21st Apr 20237:00 amRNSFORM 8 (OPD) – Allergy Therapeutics plc
20th Apr 20235:29 pmRNSProject Zebra Rule 2.9 Announcement
19th Apr 20237:00 amRNSSkin-prick testing completes in PROTECT Trial
17th Apr 20232:30 pmRNSForm 8 OPD SkyGem Acquisition Limited Replacement
17th Apr 202310:30 amRNSForm 8 (OPD) SkyGem Acquisition Limited
11th Apr 202310:10 amBUSForm 8.3 - The Allergy Therapeutics Plc
6th Apr 20232:01 pmRNS£40.75 million Facility with Equity Financing
6th Apr 20232:01 pmRNSStatement Regarding Possible Mandatory Cash Offer
6th Apr 20232:00 pmRNSTrading and Business Update
29th Mar 20237:00 amRNSPublication of Interim Results Delayed
27th Mar 20237:00 amRNSPatients dosed in VLP Peanut PROTECT trial
8th Mar 20235:28 pmRNSBlock Listing Interim Review
3rd Mar 20237:00 amRNSPDMR Dealing
7th Feb 20236:29 pmRNSResult of AGM
20th Jan 20237:00 amRNSHalf-Year Trading Update 2023
13th Jan 20235:27 pmRNSNOTICE OF 2022 ANNUAL GENERAL MEETING
3rd Jan 20237:30 amRNSSuspension - Allergy Therapeutics plc
29th Dec 202211:05 amRNSSecond Price Monitoring Extn
29th Dec 202211:00 amRNSPrice Monitoring Extension
29th Dec 20229:05 amRNSSecond Price Monitoring Extn
29th Dec 20229:00 amRNSPrice Monitoring Extension
29th Dec 20227:00 amRNSAnnual Report and Accounts Delayed
28th Dec 20227:00 amRNSDirector Resignation
8th Dec 20227:00 amRNSKey updates on Grass MATA MPL and VLP Peanut
6th Dec 20227:00 amRNSAppointment of Non-Executive Directors
21st Nov 20227:00 amRNSAppointment of Interim CFO
28th Oct 20227:00 amRNSAllergy to resume UK manufacturing production
19th Oct 20223:39 pmRNSHolding(s) in Company
17th Oct 20221:27 pmRNSAllergy Therapeutics – Result of GM
4th Oct 20227:00 amRNSUK manufacturing update
29th Sep 202212:00 pmRNSAllergy Therapeutics at Investor Meet Company
29th Sep 20227:00 amRNSSubscription and Debt Financing
29th Sep 20227:00 amRNSUnaudited Preliminary Results 2022
5th Sep 20227:00 amRNSAllergy Therapeutics at H.C. Wainwright Conference
2nd Sep 20224:50 pmRNSTotal Voting Rights
2nd Aug 202212:58 pmRNSBlock Listing Interim Review
15th Jul 20227:00 amRNSTrading Update and Notice of Results
1st Jul 20227:00 amRNSAllergy Therapeutics at EAACI Congress 2022
26th May 20227:00 amRNSNick Wykeman to step down as CFO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.